Clinical trialPhase 2Completed
Cabozantinib and Pembrolizumab in Metastatic Pancreas
Phase II Clinical Trial Evaluating Cabozantinib and Pembrolizumab in Metastatic Pancreatic Cancer
- Outcome
- Results posted; single-arm, no comparison
- Phase
- Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- 4 January 2022
- Ended
- 5 November 2024
- Enrollment
- 21 participants
- Sites
- 1
- Primary outcomes
- Progression-free Survival
- Sponsor type
- Academic / other
- Results posted
- 19 November 2025
- Last update
- 19 November 2025
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 19 November 2025
- PFS
- Progression-free SurvivalCabozantinib and pembrolizumab: 2 of 21Values: ParticipantsTime frame: 1 yearNo analysis posted for this outcome (outcome 1)
- Participants
- Cabozantinib and pembrolizumab: 21 started, 2 completed
- Serious adverse events
- Cabozantinib and pembrolizumab: 13 of 21Participants with at least one serious adverse event, of those at risk, as posted
4 secondary outcomes
- Number of Participants With Response to Therapy
- Cabozantinib and pembrolizumab 1/21 [Participants]
- Number of Participants With Complete Response
- Cabozantinib and pembrolizumab 0/21 [Participants]
- Number of Participants With Partial Response
- Cabozantinib and pembrolizumab 1/21 [Participants]
- Overall Participant Survival Rate
- Cabozantinib and pembrolizumab 2/21 [Participants]
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This study aims to evaluate cabozantinib and pembrolizumab for the treatment of metastatic pancreatic adenocarcinoma.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Progression-free Survival [1 year]. Count Of Participants, Participants. Cabozantinib and pembrolizumab (n=21): 2.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Number of Participants With Response to Therapy [1 year]. Count Of Participants, Participants. Cabozantinib and pembrolizumab (n=21): 1.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Number of Participants With Complete Response [1 year]. Count Of Participants, Participants. Cabozantinib and pembrolizumab (n=21): 0.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Number of Participants With Partial Response [1 year]. Count Of Participants, Participants. Cabozantinib and pembrolizumab (n=21): 1.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Overall Participant Survival Rate [1 year]. Count Of Participants, Participants. Cabozantinib and pembrolizumab (n=21): 2.